add wishlist show wishlist add compare show compare preloader
Category Name
Category Name
Category Name
Category Name
Category Name
Category Name

Subantimicrobial Dosing of Doxycycline for Acne and Rosacea

Subantimicrobial Dosing of Doxycycline for Acne and Rosacea
Subantimicrobial Dosing of Doxycycline for Acne and Rosacea - A Snapshot

- Subantimicrobial dosing of doxycycline is an emerging approach for treating acne and rosacea, relying on the anti-inflammatory properties of doxycycline rather than its antibacterial effects.

- Doxycycline at subantimicrobial doses (40 mg once daily) is available in various formulations overseas, but not in Australia. In the United States, Oracea® (40 mg doxycycline) is a common commercial product. In Australia, such dosing and extended release formulations require compounding.

- Doxycycline at subantimicrobial doses exerts its effect primarily by inhibiting matrix metalloproteinases (MMPs) and reducing pro-inflammatory cytokines, which play a crucial role in the pathogenesis of acne and rosacea. This dosing strategy avoids the development of antibiotic resistance, often preferred by patients.

- A study by Moore A et al compared the efficacy and safety of subantimicrobial-dose doxycycline 40 mg and doxycycline 100 mg in treating moderate acne and found that both doses were effective, but the lower dose had fewer side effects.

- Subantimicrobial doxycycline is administered as a daily oral dose of 40 mg, typically taken in the mornings with food.

- Patients treated with subantimicrobial doxycycline often experience a reduction in inflammatory lesions and erythema associated with acne and rosacea within 6 weeks.

REFERENCES

1.
Moore A, Ling M, Bucko A, Manna V, Rueda MJ. Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study. J Drugs Dermatol. 2015 Jun;14(6):581-6. PMID: 26091383.

2. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459-464.

3. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802.

4. https://www.ema.europa.eu/en/medicines/human/referrals/oracea